Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon?

References

• Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746–2751.
   PubMed Web of Science ®Google Scholar
• British Heart Foundation (BHF). Heart and circulatory disease statistics 2019. 2019 Stat Compend. 2019;April:94–96.
   Google Scholar
• England - Health and Social Care Information Centre. QOF achievement data. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/quality-and-outcomes-framework-achievement-prevalence-and-exceptions-data/2017-18
   Google Scholar
• Xu XM, Vestesson E, Paley L, et al. The economic burden of stroke care in England, wales and Northern Ireland: using a national stroke register to estimate and report patient-level health economic outcomes in stroke. Eur Stroke J. 2018;3(1):82–91.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European. Eur Heart J. 2020; 2020 Aug 29. Published online. DOI: 10.1093/eurheartj/ehaa612.
   Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 aha/acc/hrs guideline for the management of patients with atrial fibrillation: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):e125–e151.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–1201.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Freedman B, de Caterina R, et al. Stroke prevention in atrial fibrillation: past, present and future comparing the guidelines and practical decision-making. Thromb Haemost. 2017;117(7):1230–1239.
   PubMed Web of Science ®Google Scholar
• Esteve-Pastor MA, Rivera-Caravaca JM, Roldán-Rabadán I, et al. Quality of oral anticoagulation with vitamin K antagonists in ‘real-world’ patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. EP Eur. 2018;20(9):1435–1441.
   PubMed Web of Science ®Google Scholar
• Zulkifly H, Cheli P, Lutchman I, et al. Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation. Thromb Res. 2020;192:12–20.
   PubMed Web of Science ®Google Scholar
• Pandey AK, Xu K, Zhang L, et al. Lower versus standard INR targets in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Thromb Haemost. 2020;120(3):484–494.
   PubMed Web of Science ®Google Scholar
• Pastori D, Farcomeni A, Saliola M, et al. Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. Eur J Intern Med. 2018;54:34–39.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, JJV M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• NICE. NICE guideline - atrial fibrillation: management. NICE Guidel. 2014August;(2014):38. Available from: https://www.nice.org.uk/guidance/cg180
   Google Scholar
• Recommendations | venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism | Guidance | NICE.
   Google Scholar
• Larsen TB, Skjøth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin k antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Chen A, Stecker E, Warden A. B. direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559.
   PubMed Web of Science ®Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31(19):2369–2429.
   PubMed Web of Science ®Google Scholar
• John Camm A, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719–2747.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Vitolo M, Proietti M, Harrison S, et al. The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. Intern Emerg Med. 2020;15(7):1183–1192.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Al-Khatib SM, Cosi FG, et al. Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc. 2014;3(4):4.
   Web of Science ®Google Scholar
• Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the euro heart survey on atrial fibrillation. Eur Heart J. 2005;26(22):2422–2434.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Laroche C, Dan G-A, et al. A prospective survey in European society of cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) pilot general registry. EP Eur. 2014;16(3):308–319.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Laroche C, Dan GA, et al. “Real-World” antithrombotic treatment in atrial fibrillation: the eorp-af pilot survey. Am J Med. 2014;127(6):519–529.e1.
   PubMed Web of Science ®Google Scholar
• Proietti M, Laroche C, Nieuwlaat R, et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018;55:28–34.
   PubMed Web of Science ®Google Scholar
• Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) long-term general registry. EP Eur. 2018;20(5):747–757.
   PubMed Web of Science ®Google Scholar
• Lane DA, McMahon N, Gibson J, et al. Mobile health applications for managing atrial fibrillation for healthcare professionals and patients: a systematic review. EP Eur. 2020;22(10):1567–1578.
   Web of Science ®Google Scholar
• Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307–314.
   PubMed Web of Science ®Google Scholar
• Mazurek M, Halperin JL, Huisman MV, et al. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. Europace. 2020;22(1):47–57.
   PubMed Web of Science ®Google Scholar
• Potpara TS, Lip GYH, Dagres N, et al. Cohort profile The ESC EURObservational Research Programme Atrial Fibrillation III (AF III) registry. Eur Hear J - Qual Care Clin Outcomes. Published online. 2020 Jun 8. DOI: 10.1093/ehjqcco/qcaa050
   Web of Science ®Google Scholar
• Wu J, Alsaeed ES, Barrett J, et al. Prescription of oral anticoagulants and antiplatelets for stroke prophylaxis in atrial fibrillation: nationwide time series ecological analysis. EP Eur. 2020;22(9):1311–1319.
   PubMed Web of Science ®Google Scholar
• Robson J, Homer K, Ahmed Z, et al. Variation in anticoagulation for atrial fibrillation between english clinical commissioning groups: an observational study. Br J Gen Pract. 2018;68(673):e551–e558.
   PubMed Web of Science ®Google Scholar
• Ho KH, van Hove M, Leng G. Trends in anticoagulant prescribing: a review of local policies in english primary care. BMC Health Serv Res. 2020;20(1):279.
   PubMed Web of Science ®Google Scholar
• Bakhai A, Petri H, Vahidnia F, et al. Real‐world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non‐valvular atrial fibrillation patients in England. J Eval Clin Pract. Published online April21 2020; jep.13400. 10.1111/jep.13400
   Web of Science ®Google Scholar
• Loo SY, Dell’Aniello S, Huiart L, et al. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096–2106.
   PubMed Web of Science ®Google Scholar
• Alwafi H, Wei L, Naser AY, et al. Trends in oral anticoagulant prescribing in individuals with type 2 diabetes mellitus: a population-based study in the UK. BMJ Open. 2020;10(5):e034573.
   PubMed Web of Science ®Google Scholar
• Mongkhon P, Alwafi H, Fanning L, et al. Patterns and factors influencing oral anticoagulant prescription in people with atrial fibrillation and dementia: results from UK primary care. Br J Clin Pharmacol. 2020 July 23; bcp.14464. Published online. 10.1111/bcp.14464
   Web of Science ®Google Scholar
• Mazurek M, Shantsila E, Lane DA, et al. Secondary versus primary stroke prevention in atrial fibrillation: insights from the darlington atrial fibrillation registry. Stroke. 2017;48(8):2198–2205.
   PubMed Web of Science ®Google Scholar
• Campbell Cowan J, Wu J, Hall M, et al. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018;39(32):2975–2983.
   PubMed Web of Science ®Google Scholar
• Martinez C, Katholing A, Wallenhorst C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC: A cohort study. Thromb Haemost. 2016;115(1):31–39.
   PubMed Web of Science ®Google Scholar
• Orlowski A, Gale CP, Ashton R, et al. Clinical and budget impacts of changes in oral anticoagulation prescribing for atrial fibrillation. Heart. 2020 October;107(1):47–53. Published online.
   PubMed Web of Science ®Google Scholar
• Alfirevic A, Downing J, Daras K, et al. Has the introduction of direct oral anticoagulants (DOACs) in England increased emergency admissions for bleeding conditions? A longitudinal ecological study. BMJ Open. 2020;10(5):e033357.
   PubMed Web of Science ®Google Scholar
• Green L, Tan J, Morris JK, et al. A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the uk (Orange study). Haematologica. 2018;103(4):738–745.
   PubMed Web of Science ®Google Scholar
• Blann AD, Boriani G, Lip GYH. Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. EP Eur. 2016;18(10):1507–1513.
   PubMed Web of Science ®Google Scholar
• Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14(11):627–628.
   PubMed Web of Science ®Google Scholar
• Yoon M, Yang PS, Jang E, et al. Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial Fibrillation Better Care) pathway for integrated care management: a nationwide cohort Study. Thromb Haemost. 2019;19(10):1695–1703.
   Web of Science ®Google Scholar
• Proietti M, Lip GYH, Laroche C, et al. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. EP Eur. Published online. 2020 Oct 2. DOI: 10.1093/europace/euaa274
   Google Scholar
• Arbelo E, Aktaa S, Bollmann A, et al. Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace. Published online. 2020 Aug 29. 10.1093/europace/euaa253
   Web of Science ®Google Scholar
• Kotalczyk A, Mazurek M, Kalarus Z, et al. Stroke prevention strategies in high-risk patients with atrial fibrillation. Nat Rev Cardiol. 2020; Published online. 10.1038/s41569-020-00459-3
   PubMed Web of Science ®Google Scholar
• Mazurek M, Huisman MV, Lip GYH. Registries in atrial fibrillation: from trials to real-life clinical practice. Am J Med. 2017;130(2):135–145.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Cools F, Virdone S, et al. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol. 2020;76(12):1425–1436.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Laroche C, Popescu MI, et al. Improved outcomes with European society of cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the eorp-af general pilot registry. Europace. 2015;17(12):1777–1786.
   PubMed Web of Science ®Google Scholar
• Chen LY, Chung MK, Allen LA, et al. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the american heart association. Circulation. 2018;137(20):e623–e644.
   PubMed Web of Science ®Google Scholar
• Kaplan RM, Koehler J, Ziegler PD, et al. Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score. Circulation. 2019;140(20):1639–1646.
   PubMed Web of Science ®Google Scholar
• Daoud EG, Glotzer TV, Wyse DG, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: A subgroup analysis of TRENDS. Hear Rhythm. 2011;8(9):1416–1423.
   PubMed Web of Science ®Google Scholar
• Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094–2099.
   PubMed Web of Science ®Google Scholar
• Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381(20):1909–1917.
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang H, Zhang H, et al. Mobile photoplethysmographic technology to detect atrial fibrillation. J Am Coll Cardiol. 2019;74(19):2365–2375.
   PubMed Web of Science ®Google Scholar
• Kotalczyk A, Kalarus Z, Wright DJ, et al. Cardiac electronic devices: future directions and challenges. Med Devices Evidence Res. 2020;13:325–338.
   Web of Science ®Google Scholar
• Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation focus on non-vitamin k antagonist oral anticoagulants. Thromb Haemost. 2017;117(2):209–218.
   PubMed Web of Science ®Google Scholar
• Guo Y, Lane DA, Wang L, et al. Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: the mAFA (mAF‐App) II randomised trial. Int J Clin Pract. 2019;73(7): 10.1111/ijcp.13352
   Web of Science ®Google Scholar
• Guo Y, Lane DA, Chen Y, et al. Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mafa-ii randomized trial. Am J Med. 2020;123:1195–1202.e2.
   PubMed Web of Science ®Google Scholar
• Fitzgerald G, Prince C, Downing J, et al. Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics. Pharmacogenomics. 2019;20(8):599–608.
   PubMed Web of Science ®Google Scholar
• Yang T, Zhou Y, Chen C, et al. Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials. J Clin Pharm Ther. 2019;44(2):197–208.
   PubMed Web of Science ®Google Scholar
• Jorgensen AL, Prince C, Fitzgerald G, et al. Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: A matched cohort study. BMC Med. 2019;17(1):76.
   PubMed Web of Science ®Google Scholar
• Moloney E, Craig D, Holdsworth N, et al. Optimising clinical effectiveness and quality along the atrial fibrillation anticoagulation pathway: an economic analysis. BMC Health Serv Res. 2019;19(1):1007.
   PubMed Web of Science ®Google Scholar
• Lane D, Meyerhoff J, Rohner U, et al. Perceptions of atrial fibrillation, stroke risk, and oral anticoagulation treatment: an international survey. TH Open. 2018;02(3):e233–e241.
   Google Scholar
• Freedman B, Martinez C, Katholing A, et al. Residual risk of stroke and death in anticoagulant-treated patients with atrial fibrillation. JAMA Cardiol. 2016;1(3):366–368.
   PubMed Web of Science ®Google Scholar
• Gadsbøll K, Staerk L, Fosbøl EL, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38(12):899–906.
   PubMed Web of Science ®Google Scholar
• Birkinshaw A, Fry CH, Fluck D, et al. Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation. JRSM Cardiovasc Dis. 2020;9:204800402091540.
   Web of Science ®Google Scholar
• Li G, Lip GYH, Holbrook A, et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol. 2019;34(2):173–190.
   PubMed Web of Science ®Google Scholar
• Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost. 2018;118(12):2171–2187.
   PubMed Web of Science ®Google Scholar
• Chao TF, Lip GYH, Lin YJ, et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta has-bled scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost. 2018;118(4):768–777.
   PubMed Web of Science ®Google Scholar
• Chao TF, Lip GYH, Liu CJ, et al. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71(2):122–132.
   PubMed Web of Science ®Google Scholar
• Yoon M, Yang PS, Jang E, et al. Dynamic Changes of CHA 2 DS 2 -VASc score and the risk of ischaemic stroke in asian patients with atrial fibrillation: a nationwide cohort study. Thromb Haemost. 2018;118(7):1296–1304.
   PubMed Web of Science ®Google Scholar
• Chao TF, Liao JN, Tuan TC, et al. Incident co-morbidities in patients with atrial fibrillation initially with a cha 2 ds 2 -vasc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially “low-risk” patients. Thromb Haemost. 2019;119(7):1162–1170.
   PubMed Web of Science ®Google Scholar
• Nicolau AM, Corbalan R, Nicolau JC, et al. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):167–175.
   PubMed Web of Science ®Google Scholar
• Proietti M, Romiti GF, Olshansky B, et al. Comprehensive management with the abc (atrial fibrillation better care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial. J Am Heart Assoc. Published online 2020 May 6;9(10): 10.1161/JAHA.119.014932
   PubMed Web of Science ®Google Scholar
• Frederik D, Haolin X, MR A, et al. Management of atrial fibrillation in older patients by morbidity burden: insights from get with the guidelines‐atrial fibrillation. J Am Heart Assoc. 2020;9(23):e017024.
   PubMed Web of Science ®Google Scholar
• Loring Z, Shrader P, Allen LA, et al. Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. Am Heart J. 2020;219:21–30.
   PubMed Web of Science ®Google Scholar
• Khurshid S, Healey JS, McIntyre WF, et al. Population-based screening for atrial fibrillation. Circ Res. 2020;127(1):143–154.
   PubMed Web of Science ®Google Scholar
• Bassand JP, Virdone S, Goldhaber SZ, et al. Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation. Circulation. 2019;139(6):787–798.
   PubMed Web of Science ®Google Scholar
• Pritchett RV, Bem D, Turner GM, et al. Improving the prescription of oral anticoagulants in atrial fibrillation: a systematic review. Thromb Haemost. 2019;119(2):294–307.
   PubMed Web of Science ®Google Scholar
• Geng YP, Lan DH, Liu N, et al. Patient-reported treatment satisfaction with dabigatran versus warfarin in patients with non-valvular atrial fibrillation in China. Thromb Haemost. 2018;118(10):1815–1822.
   PubMed Web of Science ®Google Scholar
• Loewen PS, Ji AT, Kapanen A, et al. Patient values and preferences for antithrombotic therapy in atrial fibrillation: A narrative systematic review. Thromb Haemost. 2017;117(6):1007–1022.
   PubMed Web of Science ®Google Scholar
• Marzec LN, Wang J, Shah ND, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2475–2484.
   PubMed Web of Science ®Google Scholar
• Lee SR, Choi EK, Do HK, et al. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-Vitamin K antagonist oral anticoagulants: A nationwide population-based study. PLoS One. 2017;12(12):e0189495.
   Web of Science ®Google Scholar
• Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion-an update. Europace. 2020;22(2):184.
   PubMed Web of Science ®Google Scholar
• Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the american college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2017;70(24):3042–3067.
   PubMed Web of Science ®Google Scholar
• Lane DA, Skjøth F, Lip GYH, et al. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J Am Heart Assoc. 2017;6(5):5.
   Web of Science ®Google Scholar